A number of other brokerages have also recently issued reports on GSK. JPMorgan Chase & Co. reissued a neutral rating and issued a GBX 1,600 ($20.91) target price on shares of GlaxoSmithKline in a research report on Tuesday, August 21st. Berenberg Bank reissued a buy rating and issued a GBX 1,790 ($23.39) target price on shares of GlaxoSmithKline in a research report on Thursday, August 23rd. Liberum Capital cut GlaxoSmithKline from a buy rating to a hold rating and upped their target price for the company from GBX 1,630 ($21.30) to GBX 1,700 ($22.21) in a research report on Thursday, August 30th. Jefferies Financial Group set a GBX 1,775 ($23.19) price objective on GlaxoSmithKline and gave the company a buy rating in a research note on Thursday, August 16th. Finally, Barclays reaffirmed an overweight rating on shares of GlaxoSmithKline in a research note on Friday, August 10th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and eight have given a buy rating to the stock. The company has a consensus rating of Hold and a consensus price target of GBX 1,512.99 ($19.77).
Shares of LON GSK opened at GBX 1,437.40 ($18.78) on Tuesday. GlaxoSmithKline has a 52-week low of GBX 1,235.20 ($16.14) and a 52-week high of GBX 1,724.50 ($22.53).
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
See Also: Stop Order
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.